{
  "drug_id": "D003",
  "drug_name": "Cytovara",
  "indication": "Condition-Z",
  "modality": "peptide",
  "mechanism": "bispecific immune modulator",
  "moa_short": "Engages two targets to rebalance immune signaling.",
  "formulation": "vial for infusion",
  "route": "intravenous",
  "regimen": "3 mg/kg Q8W",
  "trial_id": "AMGN-D003-201",
  "phase": "Phase 3",
  "arms": [
    {
      "name": "Cytovara 3 mg/kg Q8W",
      "n": 283,
      "dose": "3 mg/kg Q8W"
    },
    {
      "name": "Placebo",
      "n": 232,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Condition-Z with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Proportion achieving Response-50 at Week 16",
    "endpoint_secondary": "Quality-of-life improvement at Week 12",
    "primary_effect": "62.9% vs 36.7% (\u0394 26.2%)",
    "primary_pvalue": 0.03351716286975333,
    "primary_ci": "[18.2%, 34.2%]",
    "secondary_effect": "Did not meet prespecified significance threshold",
    "discontinuation_rate_pct": 4.053862150335587
  },
  "safety": {
    "common_ae": [
      [
        "Elevated ALT",
        7.065855432689738
      ],
      [
        "Fatigue",
        5.568797933055029
      ],
      [
        "Dizziness",
        2.5046612282736156
      ],
      [
        "Arthralgia",
        2.5402725727757787
      ],
      [
        "Rash",
        2.0
      ],
      [
        "Injection-site reaction",
        2.0
      ]
    ],
    "serious_ae_rate_pct": 2.043805900687911,
    "discontinuation_ae_rate_pct": 2.1666804184043054,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.9",
  "doc_date": "2025-12-26"
}